Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Dec 14;5(23):5344-5348.
doi: 10.1182/bloodadvances.2021005020.

Macrophage activation syndrome-like (MAS-L) manifestations following BCMA-directed CAR T cells in multiple myeloma

Vanessa E Kennedy  1 , Christopher Wong  2 , Chiung-Yu Huang  3 , Swetha Kambhampati Thiruvengadam  1 , Jeffrey Wolf  1 , Thomas G Martin  1 , Nina Shah  1 , Sandy W Wong  1
Affiliations

Macrophage activation syndrome-like (MAS-L) manifestations following BCMA-directed CAR T cells in multiple myeloma

Vanessa E Kennedy et al. Blood Adv. .

Erratum in

No abstract available

PubMed Disclaimer

Figures

None
Graphical abstract
Figure 1.
Figure 1.
Ferritin, CRP, and treatment over time in patients who developed macrophage activation-like syndrome (MAS-L) following CAR T-cell therapy. Ferritin (red), C-reactive protein (CRP) (blue), and administration of tocilizumab (green triangle), systemic steroids (purple triangle), and/or anakinra (yellow) over time for the 12 patients who developed MAS-L.
See this image and copyright information in PMC

References

    1. Ali SA, Shi V, Maric I, et al. T cells expressing an anti-B-cell maturation antigen chimeric antigen receptor cause remissions of multiple myeloma. Blood. 2016;128(13):1688-1700 - PMC - PubMed
    1. Brudno JN, Maric I, Hartman SD, et al. T cells genetically modified to express an anti-B-cell maturation antigen chimeric antigen receptor cause remissions of poor-prognosis relapsed multiple myeloma. J Clin Oncol. 2018;36(22):2267-2280. - PMC - PubMed
    1. Cohen AD, Garfall AL, Stadtmauer EA, et al. B cell maturation antigen-specific CAR T cells are clinically active in multiple myeloma. J Clin Invest. 2019;129(6):2210-2221. - PMC - PubMed
    1. Raje N, Berdeja J, Lin Y, et al. Anti-BCMA CAR T-Cell therapy bb2121 in relapsed or refractory multiple myeloma. N Engl J Med. 2019;380(18):1726-1737. - PMC - PubMed
    1. Xu J, Chen LJ, Yang SS, et al. Exploratory trial of a biepitopic CAR T-targeting B cell maturation antigen in relapsed/refractory multiple myeloma. Proc Natl Acad Sci USA. 2019;116(19):9543-9551. - PMC - PubMed

Substances